ReviewWorld journal of gastroenterology2025
Explainable artificial intelligence for personalized management of inflammatory bowel disease: A minireview of recent advances.
Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial intelligence and digital transformation of gastroenterology and hepatology: A critical review of clinical applications and future challenges.World journal of hepatology · 2026Review
- Recent Advances in Artificial Intelligence for Endoscopic and Multimodal Assessment of Inflammatory Bowel Disease: A Review.International journal of general medicine · 2026Review
- The utility of artificial intelligence in visualization of pediatric gastrointestinal mucosa.Frontiers in pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Personalized management of inflammatory bowel disease (IBD) is crucial due to the heterogeneity in disease presentation, variable therapeutic response, and the unpredictable nature of disease progression. Although artificial intelligence (AI) and machine learning algorithms offer promising solutions by analyzing complex, multidimensional patient data, the "black-box" nature of many AI models limits their clinical adoption. Explainable AI (XAI) addresses this challenge by making data-driven predictions more transparent and clinically actionable. This minireview focuses on recent advancements and clinical relevance of integrating XAI for personalized IBD management. We explore the importance of XAI in prioritizing treatment and highlight how XAI techniques, such as feature-attribution explanations and interpretable model architectures, enhance transparency in AI models. In recent years, XAI models have been applied to diagnose IBD anomalies by prioritizing the predictive features for gastrointestinal bleeding and dietary intake patterns. Furthermore, studies have revealed that XAI application enhances IBD risk stratification and improves the prediction of drug efficacy and patient responses with high accuracy. By transforming opaque AI models into interpretable tools, XAI fosters clinician trust, supports personalized decision-making, and enables the safe deployment of AI systems in sensitive, individualized IBD care pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.